Creon delayed-release capsules approved for exocrine pancreatic insufficiency due to cystic fibrosis - MPR

Links shared publicly online about this topic.

2,075
total visits

Creon delayed-release capsules approved for exocrine pancreatic insufficiency due to cystic fibrosis - MPR

Creon (pancrelipase, from Solvay Pharmaceuticals) delayed-release capsules, a pancreatic enzyme product (PEP), has received FDA approval for the treatment of exocrine pancreatic insufficiency (EPI) due to cystic fibrosis (CF) or other conditions under the new guidelines for this class of drugs.

View full resource at empr.com

Tags: Pancreatic Disease, Cystic Fibrosis, Drug, Pharma, FDA, Solvay, News